Purchase this article with an account.
T. Chiba, K. Kashiwagi, K. Nakano, N. Chiba, S. Tsukahara; Effect Non–Steroidal Anti–Inflammatory Ophthalmic Solution on Intraocular Pressure Reduction by Isopropyl Unoprostone in Patients With Primary Open Angle Glaucoma or Ocular Hypertension . Invest. Ophthalmol. Vis. Sci. 2006;47(13):450.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We have recently reported that a non–steroidal anti–inflammatory drug (NSAID) ophthalmic solution may interfere with intraocular pressure (IOP) reduction by latanoprost ophthalmic solution in normal volunteers and glaucoma patients (BJO 2003, 2005). In this study, we investigate the effects of NSAID ophthalmic solution on Isopropyl unoprostone–induced IOP reduction using glaucoma patients.
Examination was conducted on 14 eyes of 14 glaucoma patients who had been administered only Isopropyl unoprostone (unoprostone) for at least six weeks. The NSAID ophthalmic solution, sodium 2–amino–3–(4–bromobenzoyl) phenylacetate sesquihydrate(bromfenac sodium hydrate, Senju Pharmaceutical, Osaka, Japan), was additionally administered for 12 weeks into one eye (NSAID group), while sodium hyaluronic acid ophthalmic solution was administered into the other eye (control group) with a double masked fashion. The IOP measurement was performed before the start of additional administration of ophthalmic solutions, 2, 4, 6, 8, 10 and 12 weeks after the start of additional administration, and 2, 4 and 6 weeks after discontinuing additional administration.
No significant difference was observed in the IOPs before additional administration of ophthalmic solution between the NSAID group(17.6 ± 3.3 mmHg) and the control group(17.4 ± 3.3 mmHg). The IOPs in the NSAID group were higher than those in the control group at 2,4,6,8 weeks following the start of additional administration, and after 6 weeks of additional administration, the difference in IOP between the two groups reached a maximum of 1.17 ± 1.75 mmHg (p=0.03), and this IOP difference was not observed following discontinuation of additional administration of ophthalmic solution.
NSAID ophthalmic solution may affect the IOP reduction by unoprostone in part.
This PDF is available to Subscribers Only